We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Pseudoephedrine on Rhinitis and Sleep

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00704496
First Posted: June 25, 2008
Last Update Posted: October 18, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Timothy Craig, Milton S. Hershey Medical Center
  Purpose
The hypothesis is that pseudoephedrine, a sympathomimetic amine commonly used as a decongestant, will decrease nasal congestion leading to increased patency of the nose and a decrease in nighttime sleep fragmentation in individuals with year round perennial allergic rhinitis (PAR). This decrease in sleep fragmentation will reduce daytime somnolence and fatigue.

Condition Intervention Phase
Rhinitis Sleep Drug: Pseudoephedrine Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Pseudoephedrine on Rhinitis and Sleep

Resource links provided by NLM:


Further study details as provided by Timothy Craig, Milton S. Hershey Medical Center:

Primary Outcome Measures:
  • Improvement of Sleep Associated With the Use of Pseudoephedrine as Compared to the Placebo [ Time Frame: 3 years ]
    sleep improvement by subjective questionnaires


Secondary Outcome Measures:
  • Improvement of Daytime Somnolence With Pseudoephedrine as Compared to Placebo [ Time Frame: 3 years ]
    daytime sleepiness by subjective questionnaires


Enrollment: 34
Study Start Date: June 2007
Study Completion Date: September 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo
Drug: Pseudoephedrine
Pseudoephedrine is a 240 mg PO per day
Other Name: Placebo
Active Comparator: Pseudoephedrine
Pseudoephedrine is a 240 mg PO per day
Drug: Pseudoephedrine
Pseudoephedrine is a 240 mg PO per day
Other Name: Placebo

Detailed Description:
The hypothesis is that pseudoephedrine, a sympathomimetic amine commonly used as a decongestant, will decrease nasal congestion leading to increased patency of the nose and a decrease in nighttime sleep fragmentation in individuals with year round perennial allergic rhinitis (PAR). This decrease in sleep fragmentation will reduce daytime somnolence and fatigue. We studied patients treated with placebo compared to FDA approved dose of pseudoephedrine and assessed sleep, QOL and daytime sleepiness.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18 to 65.
  2. History of allergic rhinitis.
  3. The ability to be placed on placebo without significant compromise in the quality of life.
  4. General good health.
  5. Ability to comply with the protocol and sign an informed consent.
  6. Have daytime sleepiness by history.
  7. Have poor sleep by history.
  8. Have fatigue by history.
  9. Have a skin test or RAST test to a perennial allergen (indoor mold, dog, cat, mite) with correlating symptoms.

Exclusion Criteria:

  1. Age fewer than 18 or over 65 years.
  2. A history of sleep apnea.
  3. Atopic diseases other than allergic rhinitis, such as atopic dermatitis or asthma.
  4. Non-allergic rhinitis.
  5. Hypertension
  6. Diabetes Mellitus
  7. Inability to tolerate pseudoephedrine
  8. Significant other diseases as determined by the investigator.
  9. Use of a research medication within 30 days.
  10. Use of a nasal steroid or topical antihistamine or decongestant within 30 days.
  11. Use of beta-blockers, antidepressants, oral decongestants, oral steroids, or H2-blockers.
  12. Excessive use of alcohol or drug abuse.
  13. Inability to stop medication use during run-in period.
  14. Use of an oral antihistamine within 1 week of enrollment.
  15. Failed to have benefit when pseudoephedrine was used for rhinitis or asthma in the past
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00704496


Locations
United States, Pennsylvania
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
Sponsors and Collaborators
Milton S. Hershey Medical Center
Investigators
Principal Investigator: Timothy J Craig, D.O. Penn State University
  More Information

Responsible Party: Timothy Craig, Timothy Craig, D.O., Milton S. Hershey Medical Center
ClinicalTrials.gov Identifier: NCT00704496     History of Changes
Other Study ID Numbers: 25325
First Submitted: June 24, 2008
First Posted: June 25, 2008
Results First Submitted: September 20, 2017
Results First Posted: October 18, 2017
Last Update Posted: October 18, 2017
Last Verified: September 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Timothy Craig, Milton S. Hershey Medical Center:
Sleep, Pseudoephedrine

Additional relevant MeSH terms:
Rhinitis
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Pseudoephedrine
Ephedrine
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Nasal Decongestants
Vasoconstrictor Agents
Central Nervous System Stimulants
Sympathomimetics
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action